company background image
IMU logo

Imugene ASX:IMU Stock Report

Last Price

AU$0.037

Market Cap

AU$297.5m

7D

-15.9%

1Y

-54.9%

Updated

21 Nov, 2024

Data

Company Financials +

Imugene Limited

ASX:IMU Stock Report

Market Cap: AU$297.5m

IMU Stock Overview

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. More details

IMU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$5M)

Currently unprofitable and not forecast to become profitable over the next 3 years


Imugene Limited Competitors

Immutep

ASX:IMM

AU$443.6m

Dimerix

ASX:DXB

AU$186.6m

Aroa Biosurgery

ASX:ARX

AU$219.0m

Clinuvel Pharmaceuticals

ASX:CUV

AU$669.3m

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share PriceAU$0.037
52 Week HighAU$0.13
52 Week LowAU$0.039
Beta3.34
11 Month Change-26.00%
3 Month Change-28.85%
1 Year Change-54.88%
33 Year Change-93.02%
5 Year Change-15.91%
Change since IPO-62.05%

Recent News & Updates

Recent updates

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Aug 29
Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Shareholder Returns

IMUAU BiotechsAU Market
7D-15.9%-3.6%1.5%
1Y-54.9%10.0%17.2%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned 17.2% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement8.9%
Biotechs Industry Average Movement9.7%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.3%
10% least volatile stocks in AU Market3.4%

Stable Share Price: IMU has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: IMU's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aLeslie Chongwww.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.

Imugene Limited Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market capAU$297.49m
Earnings (TTM)-AU$149.68m
Revenue (TTM)AU$4.97m

55.4x

P/S Ratio

-1.8x

P/E Ratio

Is IMU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMU income statement (TTM)
RevenueAU$4.97m
Cost of RevenueAU$0
Gross ProfitAU$4.97m
Other ExpensesAU$154.65m
Earnings-AU$149.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin100.00%
Net Profit Margin-3,011.66%
Debt/Equity Ratio0%

How did IMU perform over the long term?

See historical performance and comparison